Pramod John is the founder and CEO at Vivo Health. John is team leader of VIVIO Health, a startup that’s solving out of control specialty drug costs; a vexing problem faced by self-insured employers. To do this, VIVIO Health is reinventing the supply side of the specialty drug industry. VIVIO Health’s first solution requires no change to an employer’s current plans and offers significant savings by redirecting existing scripts to lower cost suppliers and managing this effort on behalf of the patient.
Prior to VIVIO Health, Pramod was founder of Oration PBC which is changing the way consumers purchase prescription medications by capturing the prescription in the physician’s office and providing all the pricing options and routing automatically. Pramod was also VP of Strategy and Innovation at McKesson, the world’s largest healthcare company. At McKesson, Pramod helped develop a solutions that leveraged advanced technologies and business process improvements to optimize healthcare delivery systems, infrastructure and supply chains.
Earlier, Pramod founded and served as CEO of PacketMotion, Inc., a venture-funded startup in the enterprise network information and policy management industry. The company was later acquired by VMWare. In addition, Pramod founded netExaminer.com, a managed-vulnerability assessment company acquired by SonicWALL (acquired by Dell).
Pramod earned his Ph.D. in Electrical Engineering from the University of Illinois at Urbana-Champaign. He serves on the Boards of Mission Aviation Fellowship, a global relief organization and 3 Crosses Church in Castro Valley, CA.
The healthcare business is broken for consumers and taxpayers in America. And we can expect to see more mergers, acquisitions and large alliances in the coming months and years, all forming in the name of trying to control rising costs and taking better care of patients. The question is: Will they? Unfortunately, the answer usually […]
These days, we’re not surprised to open the paper and see another headline about the latest Epi-pen, Martin Shkreli or yet another new drug with an exorbitant price tag that has no basis in reality. Since Sovaldi, a pill to treat Hepatitis C, hit the market at a price point of $1,000 (never mind that you could purchase it […]
Q: Some American pharmaceutical companies are well-known for pricing drugs at whatever the market will bear. In oncology, some specialty drugs seem to have price tags completely unrelated to the proven effectiveness of the drug. Your company has been taking a lead in confronting this problem. What do you envision as possible solutions? A: New […]
In both traditional healthcare and pharmaceuticals, the phrase “value-based purchasing” is all the rage. Rightfully so, we want to spend our precious healthcare dollars on the care that is most valuable. In other words, we want to pay for care and drugs that are effective and not pay for those that aren’t. Like everything else, […]
Drug manufacturers can’t catch a break, but are they the real culprit? Sure, we could wave our finger at Heather Bresch, CEO of Mylan, but didn’t we just do this to Martin Shkreli from Turing Pharmaceuticals and Michael Pearson from Valeant? The key question isn’t, who’s the offender du jour? Instead, it’s why do these […]
Over the past few months, many of us have heard of the abuses surrounding Martin Shkreli (who is in the news again after a judge set a 2017 trial date for his securities fraud case) and separately, Valeant Pharmaceuticals, which was recently under fire for drug price increases. What we haven’t heard is that these sensationalized cases […]